Therapeutic targets in childhood B-acute lymphoblastic leukemia: what about HER2/neu?

Hematol Oncol. 2021 Apr;39(2):270-272. doi: 10.1002/hon.2799. Epub 2020 Sep 17.

Authors

Margaux Camuset¹, Alice Huault¹, Audrey Grain^{1

2}, Béatrice Clémenceau², Fanny Rialland¹, Caroline Thomas¹, Patrice Chevallier^{2

3}, Marie C Béné^{2

4}, Marion Eveillard^{2

4}

Affiliations

¹ Pediatric Oncology Department, Nantes University Hospital, Nantes, France.
² CRCINA, Inserm, Team 1, Nantes, France.
³ Clinical Hematology Department, Nantes University Hospital, Nantes, France.
⁴ Hematology Laboratory, Nantes University Hospital, Nantes, France.

PMID: 32894593
DOI: 10.1002/hon.2799

No abstract available

Keywords: B-ALL; HER2/neu; childhood; minimal residual disease; therapeutic targets.

Publication types

Letter

MeSH terms

Adolescent
Adult
Antigens, CD19 / metabolism*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Child
Child, Preschool
Female
Follow-Up Studies
Humans
Infant
Male
Molecular Targeted Therapy
Neoplasm Recurrence, Local / drug therapy
Neoplasm Recurrence, Local / metabolism
Neoplasm Recurrence, Local / pathology*
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / metabolism
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology*
Prognosis
Receptor, ErbB-2 / metabolism*
Young Adult

Substances

Antigens, CD19
CD19 molecule, human
ERBB2 protein, human
Receptor, ErbB-2